Neuropathic pain / Inflammatory pain / Nociceptive pain / Morphine dose sparing

BIODOL Therapeutics develops first-in-class compounds for pain, including the first-ever specific treatment of neuropathic pain (NP). Part of the novel treatments is based on the discovery, published in Nature Communications in 2018, of the critical role of FLT3 in NP.

Moreover, recent parallel discoveries by BIODOL Therapeutics extend the scope of pain indications targeted by the company to those treated with opioids, which may help to fight the “Opioid Crisis”.